Anti-Glutamate Decarboxylase 65,67 (GAD 65,67) (FITC) Polyclonal Antibody

Cat# G4000-11-FITC-100ul

Size : 100ul

Brand : US Biological

Request more information

Contact local distributor :


Phone : +1 850 650 7790


G4000-11-FITC Glutamate Decarboxylase 65,67 (GAD 65,67) (FITC)

Clone Type
Polyclonal
Host
rabbit
Source
rat
Swiss Prot
Q05683
Isotype
IgG
Grade
Affinity Purified
Applications
FLISA IF IHC WB
Crossreactivity
Fe Hu Mo Rt
Shipping Temp
Blue Ice
Storage Temp
-20°C

Glutamic acid decarboxylase (GAD; E.C. 4.1.1.15) is the enzyme responsible for the conversion of glutamic acid to gamma-aminobutyric acid (GABA), the major inhibitory transmitter in higher brain regions, and putative paracrine hormone in pancreatic islets. Two molecular forms of GAD (65kD and 67kD, 64% aa identity between forms) are highly conserved and both forms are expressed in the CNS, pancreatic islet cells, testis, oviduct and ovary. The isoforms are regionally distributed cytoplasmically in the brains of rats and mice (Sheikh, S., et al., 1999). GAD65 is an ampiphilic, membrane-anchored protein (585aa) encoded on human chromosome10. GAD67 is cytoplasmic (594aa) and is encoded on chromosome 2. GAD expression changes during neural development in rat spinal cord. GAD65 is expressed transiently in commissural axons around E13 but is down regulated the next day while GAD67 expression increases mostly in the somata of those neurons (Phelps, P., et al., 1999). In mature rat pancreas, GAD65 and GAD67 appear to be differentially localized, GAD65 primarily in insulin-containing beta cells and GAD67 in glucagon-containing (A) cells (Li, L., et al., 1995). Changes in GAD65/GAD67 distributions have also been correlated with certain disease states such as IDDM and SMS.

Applications:
Suitable for use in Immunohistochemistry, FLISA, Western Blot and Immunofluorescence. Other applications have not been tested.

Recommended Dilutions:
Immunohistochemistry (Frozen): 1:200-1:5000
Immunohistochemistry: Paraffin sections
Western Blot: 1:1000-1:10,000. A doublet at ~65/67kD is expected.
Optimal working dilutions to be determined by researcher.

Recommended Positive Control Tissue:
Brain

Storage and Stability:
Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer.
Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Note: Applications are based on unconjugated antibody.

Applications
Product Type: Pab|Isotype: IgG|Host: rabbit|Source: rat|Concentration: As Reported |Form: Supplied as a liquid in PBS, pH 7.2. Labeled with Fluorescein isothiocyanate (FITC).|Purity: Purified by Protein A affinity chromatography|Immunogen: Synthetic peptide corresponding to DFLIEEIERLGQDL from the C-terminus of rat GAD2.|Specificity: Recognizes both molecular forms of rat glutamate decarboxylase |(GAD65 and GAD67), the enzyme which converts glutamic acid to gamma-aminobutyric acid (GABA), the major inhibitory transmitter in the higher brain region. Species Crossreactivity: human, mouse and feline||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Synthetic peptide corresponding to DFLIEEIERLGQDL from the C-terminus of rat GAD2.
Form
Supplied as a liquid in PBS, pH 7.2. Labeled with Fluorescein isothiocyanate (FITC).
Purity
Purified by Protein A affinity chromatography
Specificity
Recognizes both molecular forms of rat glutamate decarboxylase |(GAD65 and GAD67), the enzyme which converts glutamic acid to gamma-aminobutyric acid (GABA), the major inhibitory transmitter in the higher brain region. Species Crossreactivity: human, mouse and feline
References
1. Hughes, S.M., et al., Dev. Neurobiol. 69: 477-490 (2009). General References: 1. Hernandez-Montiel, H.L., et al., Dev. Biol. 255: 99-112 (2003). 2. Baizer, J.S., et al., Anat. Rec. (Hoboken) 294: 1198-1216 (2011). 3. Klusa, V., et al., Pharmacol. Biochem. Behav. pii: S0091-3057(13)00078-6 (2013). 4. Wang, X., et al., BMC Biotechnol. 8: 87 (2008).